These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36579430)

  • 1. Role of multi-targeted bioactive natural molecules and their derivatives in the treatment of Alzheimer's disease: an insight into structure-activity relationship.
    Halder D; Das S; R S J; Joseph A
    J Biomol Struct Dyn; 2023 Dec; 41(20):11286-11323. PubMed ID: 36579430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
    Yamali C; Donmez S
    Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An insight into structure-activity relationship of naturally derived biological macromolecules for the treatment of Alzheimer's disease: a review.
    Halder D; Das S; Joseph A
    J Biomol Struct Dyn; 2024 Aug; 42(12):6455-6471. PubMed ID: 37378526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease.
    Silva CFM; Pinto DCGA; Silva AMS
    Expert Opin Drug Discov; 2018 Dec; 13(12):1141-1151. PubMed ID: 30430870
    [No Abstract]   [Full Text] [Related]  

  • 6. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.
    Pathak C; Kabra UD
    Bioorg Chem; 2024 Mar; 144():107152. PubMed ID: 38290187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease.
    Mezeiova E; Chalupova K; Nepovimova E; Gorecki L; Prchal L; Malinak D; Kuca K; Soukup O; Korabecny J
    Curr Alzheimer Res; 2019; 16(9):772-800. PubMed ID: 30819078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
    Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
    Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview.
    Kumar A; Singh A; Aggarwal A
    Indian J Exp Biol; 2017 Feb; 55(2):63-73. PubMed ID: 30183230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of oxidative stress and other pathologies in Alzheimer's disease.
    Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
    Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.
    Uddin MS; Al Mamun A; Kabir MT; Ashraf GM; Bin-Jumah MN; Abdel-Daim MM
    Mol Neurobiol; 2021 Jan; 58(1):281-303. PubMed ID: 32935230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Therapeutic Approaches to Alzheimer's Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools.
    Avram S; Mernea M; Limban C; Borcan F; Chifiriuc C
    Curr Neuropharmacol; 2020; 18(8):696-719. PubMed ID: 31885353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
    Singh YP; Kumar N; Chauhan BS; Garg P
    Drug Dev Res; 2023 Dec; 84(8):1624-1651. PubMed ID: 37694498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling donepezil template into multipotent hybrids with antioxidant properties.
    Mezeiova E; Spilovska K; Nepovimova E; Gorecki L; Soukup O; Dolezal R; Malinak D; Janockova J; Jun D; Kuca K; Korabecny J
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):583-606. PubMed ID: 29529892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.
    Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N
    Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New phosphazine and phosphazide derivatives as multifunctional ligands targeting acetylcholinesterase and β-Amyloid aggregation for treatment of Alzheimer's disease.
    El-Sayed NF; El-Hussieny M; Ewies EF; Fouad MA; Boulos LS
    Bioorg Chem; 2020 Jan; 95():103499. PubMed ID: 31838287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrine derivatives and Alzheimer's disease.
    Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C
    Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.